This Article Abstract Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doble, B. W. Articles by Kardami, E. Search for Related Content PubMed PubMed Citation Articles by Doble, B. W. Articles by Kardami, E. Related Collections Other myocardial biology Arrythmias-basic studies Cell signalling/signal transduction Growth factors/cytokines

(Circulation Research. 2000;86:293.)
© 2000 American Heart Association, Inc.

Cellular Biology

The Subtype of Protein Kinase C Is Required for Cardiomyocyte Connexin-43 Phosphorylation

Bradley W. Doble, Peipei Ping, Elissavet Kardami

From the Institute of Cardiovascular Sciences (B.W.D., E.K.), University of Manitoba, St. Boniface General Hospital Research Centre, Winnipeg, Manitoba, Canada, and University of Louisville and Jewish Hospital Heart and Lung Institute (P.P.), Louisville, Ky.

Correspondence to E. Kardami, Institute of Cardiovascular Sciences, University of Manitoba, St Boniface General Hospital Research Centre, 351 Taché Ave, Winnipeg, MB, Canada, R2H 2A6. E-mail ekardami{at}sbrc.umanitoba.ca

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—Gap junctions (GJs), composed of connexins, are intercellular channels ensuring electric and metabolic coupling between cardiomyocytes. We have shown previously that an endogenous mitogenic and cardioprotective protein, fibroblast growth factor-2 (FGF-2), decreases cardiomyocyte GJ permeability by stimulating phosphorylation of connexin-43 (Cx43). Identifying the kinase(s) phosphorylating cardiac Cx43 may thus provide a way of modulating cardiac intercellular communication. Because FGF-2 activates receptors linked to protein kinase C (PKC) and mitogen-activated protein kinase, we first investigated participation of these enzymatic systems in Cx43 phosphorylation. The inhibitor PD98059 blocked activation of mitogen-activated protein kinase, but it did not prevent the FGF-2 effects on GJs. In contrast, the PKC inhibitor chelerythrine blocked the effects of FGF-2 on Cx43 phosphorylation and permeability. Because the -isoform of PKC localizes to plasma membrane sites, we examined whether it is directly involved in the FGF-2–induced Cx43 phosphorylation. In nonstimulated myocytes, PKC displayed a discontinuous pattern of localization at intercellular contact sites and partial colocalization with Cx43. Treatment with FGF-2 or phorbol 12-myristate 13-acetate induced a more continuous pattern of PKC distribution, whereas the anti-Cx43 staining appeared to overlap extensively with that of PKC. In immunoprecipitation experiments using specific anti-Cx43 antibodies, PKC but not PKC coprecipitated with Cx43. FGF-2 increased levels of coprecipitated PKC, suggesting increased association between PKC and Cx43 on stimulation. Transient gene transfer and overexpression of cDNAs coding for truncated or mutated dominant-negative forms of PKC decreased cardiomyocyte Cx43 phosphorylation significantly. We conclude that PKC mediates the FGF-2–induced effects on cardiac GJs and that PKC likely interacts with and phosphorylates cardiac Cx43 at sites of intercellular contact.

Key Words: cardiomyocyte gap junction • protein kinase C • fibroblast growth factor-2 • phosphorylation

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Gap junctions (GJs) are protein channels found at the juxtaposition of the cell membranes of 2 adjacent cells.¹ They serve as conduits, permitting the exchange of small molecules (<1 kDa), such as ions and second messengers between cells. In excitable cells such as cardiomyocytes, GJs allow action potentials to pass unhindered between coupled cells and ensure the coordinated action of the cardiac pump. GJs also mediate metabolic coupling, allowing passage of signals that regulate growth and differentiation. GJs are composed of connexins that assemble into hexameric channels known as connexons. Connexons from adjacent cells dock together to form a continuous channel linking the cytoplasms of both cells. Connexins are members of a multigene family, showing cell- and tissue-specific distribution. The predominant connexin in cardiac ventricular working cardiomyocytes is connexin-43 (Cx43).^{1 2 3}

Cx43 is phosphorylated on serine and threonine residues, although tyrosine phosphorylation is also found in some instances.^{1 4} Phosphorylation of Cx43 is thought to be required for proper synthesis and assembly of connexins into GJs^{5 6} and regulates electric conductance and permeability to small molecules.⁷ Although tyrosine phosphorylation of Cx43 has been linked to decreased gap junctional intercellular communication (GJIC),¹ phosphorylation of Cx43 on serine has been associated with both increased and decreased GJIC. Of the various signaling cascades involving serine/threonine kinases, increases in cAMP and subsequent activation of protein kinase A stimulate GJIC,^{8 9 10} whereas activation of mitogen-activated protein kinase (MAPK) or protein kinase C (PKC) has been associated with decreased GJIC.^{11 12 13} The MAPKs are serine/threonine kinases activated downstream of the ras-raf pathway by many mitogens and other effectors.¹⁴ MAPK is proposed to be directly responsible for increasing the phosphorylation of Cx43 on serine, leading to inhibition of communication in epithelial cell lines.¹¹

PKC is a family of several (at least 12) phospholipid-dependent serine/threonine protein kinases.¹⁵ The PKC family has been implicated as an intracellular mediator of several neurotransmitters, hormones, tumor promoters, 1-adrenergic agonists, and phorbol esters, and it is important in the regulation of growth, differentiation, cell death, and neurotransmission.¹⁵ The following 3 PKC subfamilies have been described: conventional PKC (PKC, -ß1, -ß2, and -; activated by Ca²⁺ and phorbol esters), novel PKC (PKC-, -, and -; not regulated by Ca²⁺), and atypical PKC (not activated by Ca²⁺ or phorbol esters). Different isoforms may perform distinct functions, as suggested by their differential pattern of localization, differences in condition of activation, and some differences in substrate specificity.^{15 16}

We have previously shown that stimulation of neonatal rat cardiomyocytes by the mitogen fibroblast growth factor (FGF)-2 decreases metabolic coupling and increases the phosphorylation of Cx43 on serine.¹⁷ Binding of FGF-2 to its tyrosine kinase receptor(s) initiates a signal transduction cascade that has been shown to activate both the MAPK and PKC pathways in cardiomyocytes.^{18 19} In this work, by using specific inhibitors, we have established that the PKC but not the MAPK pathway is involved in the FGF-2–induced effects on cardiomyocyte Cx43. In addition, we provide evidence consistent with the notion that the PKC isoform is directly involved in mediating the FGF-induced cardiomyocyte Cx43 phosphorylation.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
We obtained recombinant human FGF-2 from Upstate Biotechnology; chelerythrine from Research Biochemicals International; PD98059 from New England Biolabs; cell culture media DMEM/F12, F10, and trypsin from GIBCO/BRL; FBS from Hyclone; and all other chemicals from Sigma. Recombinant rat FGF-2 was produced as described.¹⁹

Primary Antibodies
Polyclonal rabbit antibodies to PKC and PKC and the corresponding immunizing peptides were obtained from Santa Cruz Biotechnology, monoclonal mouse antibodies to Cx43 and PKC from Transduction Laboratories, and polyclonal rabbit antibody to dually phosphorylated MAPK (anti-ACTIVE MAPK) from Promega.

Rabbit Anti-Cx43 Antibodies
A keyhole limpet hemocyanin–conjugated peptide corresponding to residues 368 to 382 of the carboxyl terminus of Cx43 was synthesized by Quality Controlled Biochemicals and used to produce a rabbit antiserum to Cx43. It was used at 1:50 000 or 1:5000 dilution for Western blotting or immunofluorescence, respectively.

Culture
Neonatal rat cardiomyocyte cultures were obtained as described.¹⁷ Cells, plated at 6 to 8x10⁵ per 35-mm dish, were maintained for 6 days in maintenance medium (0.5% FBS–DMEM/F12, containing 20 nmol/L selenium, 10 µg/mL insulin, 10 µg/mL transferrin, and 2 mg/mL BSA), and the medium was replaced every 48 hours. Two hours before treatments, the medium was changed to fresh maintenance medium minus serum.

Cx43 Phosphorylation
Cx43 phosphorylation was performed as described.¹⁷ Chelerythrine and calphostin-C (both at 1 µmol/L) were added to the cells 15 minutes before the addition of FGF-2. PD98059 (50 µmol/L) was added to cells 1 hour before FGF-2. Myocytes were stimulated with FGF-2 (10 ng/mL) for 15 minutes at 37°C. Subsequently, cells were lysed as described.¹⁷ Protein content was determined using the bicinchoninic acid assay. Each sample (100 µg) in modified radioimmunoprecipitation buffer (1% NP-40, 0.1% SDS, 0.25% deoxycholate, and 150 mmol/L NaCl) was immunoprecipitated using 2 µL of rabbit anti-Cx43 serum; detection of ³²P-labeled Cx43 was as described.¹⁷

Scrape Loading and Immunofluorescence
Scrape loading and immunofluorescence were performed as described.¹⁷

Cx43/PKC Coimmunoprecipitation
Myocytes kept in 0.5% FBS in DMEM/F12 medium for 6 days were treated with recombinant rat FGF-2 or vehicle. Myocyte lysates in cold coimmunoprecipitation buffer (containing 1% NP-40; 10% glycerol; in mmol/L, HEPES [pH 7.5] 50, NaCl 100, EDTA 1, ß-glycerophosphate 20, NaF 10, sodium orthovanadate 1, and PMSF 1; and 2 µg/mL each of leupeptin, pepstatin, aprotinin, and E-64) were processed for immunoprecipitation with anti-Cx43 antibodies.¹⁷ Immunoprecipitated protein was analyzed by Western blotting for immunoreaction with anti-PKC or anti-PKC antibodies (1:2000 dilution). Antigen-antibody complexes were visualized by an enhanced chemiluminescence reaction (SuperSignal kit; Pierce).

Transfection With PKC_(1-401)
We used a cDNA plasmid lacking the catalytic domain of murine PKC_(1-401) in the pSVK3 vector, described by Cai et al,²⁰ and a modified calcium phosphate transfection method.²¹

Infection With Ad.PKC(DN)
A dominant-negative mutant of PKC(DN) was obtained through site-directed mutagenesis of the rabbit PKC.²² Cardiomyocytes were infected with Ad.PKC(DN) or with non-PKC-DN–expressing virus at a multiplicity of infection of 50.

An expanded Materials and Methods section is available online at http://www.circresaha.org.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Effects of FGF-2 on GJs Are Not Mediated by MAPK
To assess the activation status of MAPK in cardiac myocytes, we used antibodies that specifically recognize the dually phosphorylated (and thus activated) species of MAPK in Western blots of cell lysates. As shown in Figure 1A, untreated control cardiomyocytes had barely detectable levels of the activated MAPK. FGF-2 stimulated dual phosphorylation, and thus, activation, of the 42- and 44-kDa MAPK in cardiac myocytes, as shown before.^{18 19} Pretreatment with the mitogen-activated protein kinase/extracellular signal–regulated kinase-1 (MEK1) inhibitor PD98059 (50 µmol/L) completely blocked the FGF-2 activation of MAPK.

View larger version (39K): [in this window] [in a new window]   Figure 1. MAPK inhibition and FGF-2–mediated Cx43 phosphorylation. A, Western blot of myocyte lysates from cultures treated with the MEK1 inhibitor PD98059 and/or FGF-2, as indicated, and probed with anti-ACTIVE MAPK antibodies. B, Autoradiographic detection of 32P-labeled Cx43 immunoprecipitated from cardiac myocytes treated with PD98059 and/or FGF-2, as indicated. C, Representative images of fluorescent dye (6-carboxyfluorescein) transfer (introduced by scrape loading) between myocytes treated with PD98059 and/or FGF-2, as indicated. Length of arrows indicates distance of dye migration from primary-loaded cells at the scrape line. Bar=50 µm. D, Combined data from 3 experiments shown in panel C, comparing maximal dye migration distance under different conditions, as indicated. Data are mean±SEM.

Having established that FGF-2 does stimulate MAPK and that we can block this activation fully with the MEK1 inhibitor, we proceeded to examine whether MAPK activation mediated the FGF-2–induced changes in the phosphorylation of Cx43. As can be seen in Figure 1B, complete MAPK inhibition did not prevent the increase in Cx43 phosphorylation induced by FGF-2.

We then examined whether MAPK mediated the effects of FGF-2 on GJs. When confluent cardiomyocytes were loaded with the dye 6-CF under control conditions, dye movement from the primary-loaded cells through adjacent cells in the monolayer was clearly evident (Figure 1C-i; "maximal" dye coupling). As we showed before, FGF-2 induced a clear decrease in dye migration between myocytes (Figure 1C-iii; "minimal" coupling). PD98059 pretreatment did not affect maximal or minimal dye migration (Figure 1C-ii and 1C-iv), indicating that MAPK activation by FGF-2 was not affecting the GJ-mediated dye transfer. Combined semiquantitative data on dye migration from 3 separate experiments are shown in Figure 1D.

Effects of FGF-2 on GJs Are Mediated by PKC
Cardiac myocytes were pretreated with the specific PKC inhibitor chelerythrine (1 µmol/L) 15 minutes before stimulation with FGF-2 for 15 minutes. As seen in Figure 2A, this had no effect on basal Cx43 phosphorylation, but it did completely block the increase in Cx43 phosphorylation induced by FGF-2. We also used calphostin C as a specific PKC inhibitor²³ ; at 1 µmol/L, calphostin C pretreatment for 15 minutes reduced baseline levels, as well as FGF-2–induced levels of Cx43 phosphorylation (Figure 2B). Chelerythrine pretreatment did not prevent the MAPK activation induced by FGF-2 (Figure 2C). Chelerythrine and calphostin appeared to have different effects on the baseline levels of Cx43 phosphorylation, possibly as a result of multiple actions of these inhibitors.

View larger version (40K): [in this window] [in a new window]   Figure 2. PKC inhibition and FGF-2–mediated Cx43 phosphorylation. A, Autoradiographic detection of 32P-labeled Cx43 immunoprecipitated from cardiac myocytes treated with chelerythrine (Chel.) and/or FGF-2, as indicated. B, Autoradiographic detection of 32P-labeled Cx43 immunoprecipitated from cardiac myocytes treated with calphostin-C (CalC.) and/or FGF-2, as indicated. C, Western blot of myocyte lysates from cultures treated with chelerythrine and/or FGF-2, as indicated, and probed with anti-ACTIVE MAPK antibodies. D, Representative images of fluorescent dye (6-CF) transfer between myocytes treated with chelerythrine and/or FGF-2, as indicated. Length of arrows indicates distance of dye migration from primary-loaded cells at the scrape line. Bar=50 µm. E, Combined data from 3 experiments shown in panel D, comparing maximal dye migration distance under different conditions, as indicated. Data are mean±SEM.

In scrape-loading assays, chelerythrine did not affect the migration of 6-CF dye between myocytes compared with controls (Figure 2D). The FGF-2 decrease in dye migration (Figure 2D-iii) was completely prevented when FGF-2 was added in the presence of chelerythrine (Figure 2D-iv). Combined semiquantitative data of dye migration from 3 separate experiments are shown in Figure 2E.

Immunolocalization of PKC and Cx43 Before and After Stimulation
In quiescent cardiomyocytes, PKC produced an interrupted pattern of localization to areas of intercellular contact (Figure 3A). This localization pattern was very similar to that of cadherin (B.W.D., E.K., unpublished observations, 1999); cadherin is an intercellular attachment protein and a component of adherens junctions and desmosomes, all of which are present at intercalated disks.²⁴ In FGF-2–stimulated myocytes, the staining pattern of PKC appeared more continuous in areas of cell-cell contact (Figure 3D).

View larger version (34K): [in this window] [in a new window]   Figure 3. Localization of PKC and Cx43 to sites of intercellular contact. A, B, D, and E, Double immunofluorescence labeling of cardiac myocytes for PKC and Cx43 (green and red, respectively). C and F, Simultaneous staining for both fluorochromes. A through C, Myocytes under control, unstimulated conditions. D through F, Myocytes stimulated with FGF-2. Areas of colocalization appear yellow. Arrows in B and C point to regions where Cx43 and PKC do not overlap. In panels E and F, arrows indicate regions of overlap between PKC and Cx43 staining. Bar=50 µm.

Under control, unstimulated conditions, Cx43 staining with a monoclonal antibody produced the familiar discontinuous punctate pattern characteristic of GJs. Areas of apparent colocalization with PKC were present, producing the yellow color seen in Figure 3C, as were areas of apparently exclusive localization of either PKC (staining green) or Cx43 (staining red). A representative image is shown in Figure 3C. On stimulation with FGF-2, extensive colocalization of Cx43 and PKC was observed, as might be predicted by the more extensive localization of PKC to sites of cell-cell contact shown above (Figure 3C). A typical image of PKC and Cx43 colocalization on FGF-2 treatment is shown in Figure 3F.

Treatment of cardiomyocytes with 10 nmol/L phorbol 12-myristate 13-acetate (PMA) for 15 minutes produced changes in PKC localization that were identical to those induced by FGF-2 (Figure 4). Again, the discontinuous pattern of staining for anti-PKC was prevalent in the controls (A), whereas PMA-treated myocytes displayed mostly an intense, continuous if irregular staining along cell contact sites (B). Incidence of areas staining only for Cx43 appeared higher in control, compared with PMA-treated, myocytes (C).

View larger version (29K): [in this window] [in a new window]   Figure 4. Immunolocalization of PKC and Cx43 in control and PMA-treated cardiomyocytes. Cells were stained for PKC (green) and Cx43 (red). A and C, Unstimulated myocytes. B and D, PMA-stimulated myocytes. Bar=20 µm.

Coimmunoprecipitation of Cx43 and PKC
To explore the possibility of a direct interaction between Cx43 and PKC, we used anti-Cx43–specific antibodies to immunoprecipitate Cx43 and interacting protein(s) from control and stimulated cell lysates. Typical results are shown in Figure 5. Western blot analysis of immunoprecipitated samples revealed the presence of an anti-PKC reactive band migrating at 90 kDa (Figure 5A); the only other bands detected by the anti-PKC antibody were those of the rabbit IgG (as expected). In contrast, an anti-PKC antibody preparation did not detect any protein band at 82 kDa (corresponding to the expected size for PKC), even after very prolonged exposure; under these conditions the anti-PKC antibody did eventually detect some bands, presumably nonspecifically, the intensity of which did not change (Figure 5B). Levels of the 90-kDa PKC were significantly elevated in immunoprecipitates from FGF-2–treated samples compared with control samples (Figure 5C, n=4).

View larger version (38K): [in this window] [in a new window]   Figure 5. Coprecipitation of PKC with anti-Cx43 antibodies. A and B, Western blot analyses of protein immunoprecipitated (I.P.) with polyclonal anti-Cx43 antibodies and probed for PKC (A) and PKC (B). Lane 1, Protein from unstimulated myocytes; lane 2, protein from FGF-2–stimulated myocytes. Migration of immunoglobulin (IgG), PKC, and molecular mass markers is indicated. C, Densitometric quantification of coprecipitated PKC, as shown in panel A. Asterisk indicates statistically significant differences between FGF-2–treated and control samples (n=4, P<0.05, Student t test). Data are mean±SEM.

Effects of Inhibition of PKC on Cx43 Phosphorylation
Cardiac myocytes were transfected with a truncated form of murine PKC, PKC_(1-401), which was shown previously to act as a dominant-negative inhibitor of PKC.²⁰ Gene transfer was achieved using a modified calcium-phosphate protocol,²¹ resulting in nearly 20% transfection efficiency of myocytes (B.W.D., E.K., unpublished observations, 1998). Expression of the truncated PKC in transfected cells was assessed by Western blotting with an antibody raised against the N terminus of PKC and shown in Figure 6A. Native PKC levels remain the same in cells transfected with vector or with PKC_(1-401) (Figure 6A). Levels of Cx43 phosphorylation, assessed by immunoprecipitation of ³²P-labeled Cx43 and corrected for variations in total Cx43 present in the samples, were significantly decreased in cultures expressing the PKC_(1-401) compared with vector-transfected controls (Figure 6B and 6C).

View larger version (18K): [in this window] [in a new window]   Figure 6. Effect of PKC(1-401) on Cx43 phosphorylation. A, Detection of PKC(1-401) expression by Western blotting. Myocytes were transfected by the calcium phosphate method with vector or the cDNA coding for PKC(1-401), as indicated. Migration of the endogenous PKC (at 90 kDa) and the truncated PKC(1-401) is indicated. B, 32P-labeled Cx43 was quantified by immunoprecipitation from labeled myocyte lysates and analysis by SDS/PAGE, followed by autoradiography and densitometry. Levels of 32P-labeled Cx43 were corrected for the Cx43 content of each lysate, determined by parallel Western blotting and densitometry. Cx43 phosphorylation in control cultures was arbitrarily defined as 100%, and values from the treated cultures were expressed relative to control values. Cultures were transfected with the cDNA for PKC(1-401) or vector, as indicated (n=4, *P<0.05, unpaired t test). C, Representative autoradiograph of 32P-labeled Cx43 immunoprecipitated from myocytes transfected with vector or PKC(1-401) cDNA. Migration of molecular mass markers (A and C) is shown in kDa.

Cardiac myocytes were infected with a cDNA coding for a mutated, dominant-negative form of PKC, Ad.PKC(DN), using an adenoviral vector, as described.²² The mutated PKC is still capable of binding to the membrane but cannot phosphorylate its target(s).²² Abundant expression of PKC(DN) was detected by Western blotting, using conditions of enhanced chemiluminescence reagent development that do not detect the endogenous PKC (Figure 7A). Longer exposure resulted in detection of the endogenous isoform (as in Figure 6A), whereas the lane containing lysates from Ad.PKC(DN)–expressing myocytes appeared completely black. Levels of ³²P-labeled Cx43 decreased sharply in cultures expressing the Ad.PKC(DN) compared with controls treated with the virus alone (Figure 7B and 7C).

View larger version (21K): [in this window] [in a new window]   Figure 7. Effect of Ad.PKC(DN) on Cx43 phosphorylation. A, Detection of Ad.PKC(DN) by Western blotting. Myocytes were infected with adenovirus alone or with Ad.PKC(DN), as indicated. B, Procedures as in Figure 6B. Cultures were infected with adenovirus alone or Ad.PKC(DN) (n=3, *P<0.05, unpaired t test). C, Representative autoradiograph of 32P-labeled Cx43 immunoprecipitated from myocytes transfected with vector alone or Ad.PKC(DN). Migration of molecular mass markers (A and C) is shown in kDa.

The adenoviral vector allowed for high transfection efficiency (>95%) of cardiac myocytes, determined by staining transfected myocytes for PKC with a monoclonal antibody preparation. As shown in Figure 8A, the antibody reacts very faintly with endogenous PKC in vector-infected myocytes; however, it clearly stained the cytosol and intercellular contact sites of PKC(DN)-infected cells (Figure 8B and 8C). Figure 8B was photographed under identical exposure conditions as in Figure 8A to illustrate differences in staining intensity. Figure 8C was underexposed to allow a better distinction between cytosolic and membrane-associated staining. Simultaneous staining for nuclei is also shown in Figure 8C.

View larger version (77K): [in this window] [in a new window]   Figure 8. Expression of Ad.PKC(DN) in cardiac myocytes. Shown are immunofluorescence staining for PKC (red) using the monoclonal antibody preparation and nuclear staining (blue) with Hoechst 33342. A, Myocytes infected with adenovirus alone show background levels of anti-PKC staining. B, Myocytes infected with Ad.PKC(DN) and photographed under conditions of film exposure identical to those in panel A show strong expression of PKC(DN). C, Same field as in panel B, photographed under decreased conditions of film exposure. Bar=50 µm.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
Our objective was to determine which signal transduction pathway(s) is involved in the FGF-2–mediated Cx43 phosphorylation in cardiomyocytes. Novel findings here are that (1) MAPK activation is apparently not required, (2) PKC mediates the FGF-2–induced Cx43 phosphorylation, (3) PKC and Cx43 colocalize to areas of intermyocyte contact, (4) there is an association between PKC and Cx43 that is enhanced by FGF-2, and (5) PKC is required for the phosphorylation of Cx43.

Cx43 phosphorylation is an important modulator of GJIC and affects conductance, metabolic coupling, growth, and differentiation.^{1 25} Multiple phosphorylation sites, potential targets of several groups of kinases, suggest that Cx43 may serve as a discriminating sensor of change^{1 25} in the cellular environment. Identification of the kinase(s) and phosphatase(s) involved directly in altering the phosphorylation status of Cx43 may provide a way of interfering in situations such as arrhythmias,²⁶ uncontrolled growth²⁷ in the case of cancer cells, or inability to regenerate in terminally differentiated cells such as cardiomyocytes.

FGF-2 triggers signaling from tyrosine kinase plasma membrane receptors, which are also present in the cardiomyocyte and are known to activate the phosphoinositide pathway leading to PKC stimulation, as well as the ras-raf-MAPK pathway.²⁸ We have confirmed that FGF-2 activates both MAPK and PKC signaling in the cardiomyocyte.¹⁹ Both MAPK and PKC enzymes have been implicated in mediating Cx43 phosphorylation.^{11 12 13} Thus, we used specific inhibitors of these pathways to determine their participation in the FGF-2 effects on cardiac GJs. The inhibitor PD98059, which completely blocked the FGF-2–induced dual phosphorylation, and thus, presumably the activation, of MAPK, failed to prevent the FGF-2–induced Cx43 phosphorylation and the effects of this factor on dye migration. Furthermore, MAPK remained active when the FGF-2 effects on Cx43 phosphorylation and dye coupling were blocked. Overall, our data did not indicate an obvious involvement of the MAPK pathway on FGF-2–induced effects on Cx43 phosphorylation and dye-transfer assessed by the technique of scrape loading. Our findings differ from those of Warn-Cramer et al¹¹ and Kanemitsu and Lau,²⁹ who have presented evidence that MAPK mediates the epidermal growth factor–triggered increases in Cx43 phosphorylation in a mouse fibroblast embryonic cell line. In yet another cell system, the TF1B rat liver epithelial cells, platelet-derived growth factor disruption of GJIC required both PKC and MAPK activation.²⁸ Thus, it is likely that Cx43 phosphorylation and regulation of GJIC by growth factors recruits different signal transduction pathways, in a growth factor–specific as well as cell type–specific manner. In agreement, we did not detect any effects of epidermal growth factor on cardiomyocyte Cx43 phosphorylation (B.W.D., E.K., unpublished observations, 1999).

We then investigated the involvement of the PKC pathway. Both chelerythrine and calphostin C prevented the FGF-2–induced changes in Cx43 phosphorylation, indicating that PKC is necessary for this event to occur. Chelerythrine, furthermore, abolished the effect of FGF-2 of dye migration, indicating that PKC mediated the FGF-2 decrease in cardiomyocyte dye coupling, and strengthening the link between effects on connexin phosphorylation and GJ permeability. Our data are in agreement with several previous reports that have shown that PKC decreases coupling and increases Cx43 phosphorylation.^{12 13 30 31}

Cx43 is an integral plasma membrane protein. We investigated the possibility that PKC, which translocates to membrane sites on activation, may be directly involved in the phosphorylation of Cx43. This notion is supported by the fact that the cytosolic carboxyl-terminal half of the Cx43 molecule has several serines that could serve as PKC substrates.³² The PKC family has, however, at least 12 members; it would thus be important to identify which isoform(s) is involved in Cx43 phosphorylation. Colocalization of the various PKC isoforms with their putative substrates is proposed to ensure their preferential and rapid phosphorylation on activation, and there is evidence suggesting that PKC binds to specific anchoring proteins, such as the RACKS (receptors for activated C kinase), located at various subcellular sites.¹⁶ Subcellular localization of the PKCs could help identify their physiologically relevant substrates; conversely, if Cx43 is a direct substrate for a particular PKC, one would expect colocalization of that isoform with Cx43. The calcium-independent PKC has been reported to localize to intercalated disk–like sites on stimulation with PMA.³³ PKC is stimulated by FGF-1³⁴ and FGF-2¹⁹ ; FGF-2 induced increased association of PKC with the cardiac myocyte membrane fraction in neonatal and adult cardiomyocytes.^{19 35} We thus considered PKC as a potential candidate for mediating Cx43 phosphorylation.

We detected PKC in association with cardiomyocyte plasma membrane and cell-cell contact sites irrespectively of stimulation, but we also saw a change from an interrupted pattern of staining in control cells to a more continuous pattern on stimulation with FGF-2 or PMA. Our findings suggest that a fraction of PKC is localized to the plasma membrane under all conditions, in contrast to Disatnik et al,³³ who detected PKC at intercalated disks only in stimulated cells. It is possible that this reflects differences in culture conditions and in "baseline" levels of PKC activation. Our immunofluorescence findings have been confirmed by Western blotting analysis of cardiac sarcolemmal membranes from nonstimulated adult hearts and neonatal myocytes.^{19 35} Furthermore, as discussed below, PKC coprecipitated with Cx43 irrespectively of stimulation, a finding reinforcing the validity of our immunofluorescence studies.

The continuous pattern of PKC localization at intercellular contact sites on stimulation, in conjunction with the increased association of PKC with membranes detected by Western blotting,³⁵ would suggest that additional PKC is translocated to previously unoccupied plasma membrane sites. It is also possible that some redistribution of membrane-associated PKC may occur on stimulation. FGF-2 and PMA induced the same qualitative changes in the distribution of membrane PKC, in agreement with the notion that FGF-2 stimulates this PKC isoform in cardiac myocytes.

The colocalization and coimmunoprecipitation studies point to an interaction between PKC and Cx43 at cell-cell contact sites, an interaction that becomes more extensive in stimulated cells. Interaction between a serine-threonine kinase and a potential substrate under activation conditions known to result in increased substrate phosphorylation offers strong support to the notion that PKC can phosphorylate Cx43 on activation directly. It is also possible that the PKC-mediated decrease in the permeability of Cx43 GJs to dyes may be a consequence not only of a potential conformational change caused by phosphorylation, but also of the physical association between the 2 proteins, resulting in obstruction of the pore. Work from Calero et al,³⁶ Homma et al,³⁷ and Stergiopoulos et al³⁸ has strongly pointed to the possibility of such interactions mediating GJs permeability, although very few candidate proteins have been identified up until now.

To examine whether there is a cause-and-effect relationship between PKC and Cx43 phosphorylation in the intact myocyte, we used expression of a dominant-negative truncated PKC.²⁰ In cultures expressing the PKC_(1-401), a significant reduction of Cx43 phosphorylation was achieved, despite the relatively low transfection efficiency of cardiomyocytes under these conditions. It is possible, however, that the truncated PKC, lacking the catalytic carboxyl terminus, may not be very effective in targeting plasma membrane proteins such as Cx43.³⁹ We therefore used expression also of a mutated PKC that retains its ability for membrane localization and has been shown to act very effectively in a dominant-negative fashion²² ; adenoviral infection ensured high levels of expression in virtually all myocytes. Under these conditions, we were able to show a dramatic decrease in Cx43 phosphorylation in cultures expressing the dominant-negative PKC, demonstrating that active PKC is required for Cx43 phosphorylation.

Our data offer additional support to the notion that individual PKC isoforms possess distinct biological functions. PKC, another PKC isoform that (1) is activated by FGF-2, (2) is present in myocytes, and (3) has been localized to plasma membrane sites,³³ did not coprecipitate with Cx43, a finding indicating selectivity of interaction between the PKC species and Cx43. In addition, expression of a truncated, dominant-negative form of PKC³⁵ had no effect on Cx43 phosphorylation (B.W.D., E.K., unpublished observations, 1999).

PKC has been implicated in contractility, cardioprotection, and preconditioning. There has, however, been no information up until now as to what the potential targets of PKC may be. Evidence presented in this article points to Cx43, a plasma membrane GJ channel–forming protein, as a target for PKC. It is possible that the above PKC-mediated processes of cardioprotection and/or contractility may require alterations in Cx43 and channel pore permeability. It is of interest that anesthetics are cardioprotective and also cause decreased GJIC.⁴⁰

Finally, whereas PKC is linked to stimulation of proliferation,⁴¹ Cx43 is regarded as a growth suppressor.⁴² FGF-2 is a well-characterized mitogen. It is logical, therefore, to speculate that the FGF-2–induced proliferation of cardiomyocytes requires involvement of PKC, increased Cx43 phosphorylation, and decreased intercellular coupling.

	Acknowledgments

 
This study was supported by the Medical Research Council of Canada and the Heart and Stroke Foundation of Canada. B.W.D. was a recipient of studentships from the Heart and Stroke Foundation of Canada and the Manitoba Health Research Council. We thank Dr Geoffrey M. Cooper (Department of Biology, Boston University, Mass) for the generous gift of the cDNAs for the truncated PKC and PKC.

Received September 16, 1999; accepted November 18, 1999.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Goodenough DA, Goliger JA, Paul DL. Connexins, connexons, and intercellular communication. Annu Rev Biochem. 1996;65:475–502.[Medline] [Order article via Infotrieve]

2. Darrow BJ, Laing JG, Lampe PD, Saffitz JE, Beyer EC. Expression of multiple connexins in cultured neonatal rat ventricular myocytes. Circ Res. 1995;76:381–387.[Abstract/Free Full Text]

3. Beyer EC, Paul DL, Goodenough DA. Connexin43: a protein from rat heart homologous to a gap junction protein from liver. J Cell Biol. 1987;105:2621–2629.[Abstract/Free Full Text]

4. Crow DS, Kurata WE, Lau AF. Phosphorylation of connexin43 in cells containing mutant src oncogenes. Oncogene. 1992;7:999–1003.[Medline] [Order article via Infotrieve]

5. Laird DW, Castillo M, Kasprzak L. Gap junction turnover, intracellular trafficking, and phosphorylation of connexin43 in brefeldin A-treated rat mammary tumor cells. J Cell Biol. 1995;131:1193–1203.[Abstract/Free Full Text]

6. Musil LS, Goodenough DA. Biochemical analysis of connexin43 intracellular transport, phosphorylation, and assembly into gap junctional plaques. J Cell Biol. 1991;115:1357–1374.[Abstract/Free Full Text]

7. Moreno AP, Saez JC, Fishman GI, Spray DC. Human connexin43 gap junction channels: regulation of unitary conductances by phosphorylation. Circ Res. 1994;74:1050–1057.[Abstract/Free Full Text]

8. Darrow BJ, Fast VG, Kleber AG, Beyer EC, Saffitz JE. Functional and structural assessment of intercellular communication: increased conduction velocity and enhanced connexin expression in dibutyryl cAMP-treated cultured cardiac myocytes. Circ Res. 1996;79:174–183.[Abstract/Free Full Text]

9. Chanson M, White MM, Garber SS. cAMP promotes gap junctional coupling in T84 cells. Am J Physiol. 1996;271:C533–C539.[Abstract/Free Full Text]

10. Atkinson MM, Lampe PD, Lin HH, Kollander R, Li XR, Kiang DT. Cyclic AMP modifies the cellular distribution of connexin43 and induces a persistent increase in the junctional permeability of mouse mammary tumor cells. J Cell Sci. 1995;108:3079–3090.[Abstract]

11. Warn-Cramer BJ, Cottrell GT, Burt JM, Lau AF. Regulation of connexin-43 gap junctional intercellular communication by mitogen-activated protein kinase. J Biol Chem. 1998;273:9188–9196.[Abstract/Free Full Text]

12. Kwak BR, Saez JC, Wilders R, Chanson M, Fishman GI, Hertzberg EL, Spray DC, Jongsma HJ. Effects of cGMP-dependent phosphorylation on rat and human connexin43 gap junction channels. Pflugers Arch. 1995;430:770–778.[Medline] [Order article via Infotrieve]

13. Saez JC, Nairn AC, Czernik AJ, Fishman GI, Spray DC, Hertzberg EL. Phosphorylation of connexin43 and the regulation of neonatal rat cardiac myocyte gap junctions. J Mol Cell Cardiol. 1997;29:2131–2145.[Medline] [Order article via Infotrieve]

14. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J. 1995;9:726–735.[Abstract]

15. Newton AC. Regulation of protein kinase C. Curr Opin Cell Biol. 1997;9:161–167.[Medline] [Order article via Infotrieve]

16. Mochly-Rosen D, Gordon AS. Anchoring proteins for protein kinase C: a means for isozyme selectivity. FASEB J. 1998;12:35–42.[Abstract/Free Full Text]

17. Doble BW, Chen Y, Bosc DG, Litchfield DW, Kardami E. Fibroblast growth factor-2 decreases metabolic coupling and stimulates phosphorylation as well as masking of connexin43 epitopes in cardiac myocytes. Circ Res. 1996;79:647–658.[Abstract/Free Full Text]

18. Bogoyevitch MA, Glennon PE, Andersson MB, Clerk A, Lazou A, Marshall CJ, Parker PJ, Sugden PH. Endothelin-1 and fibroblast growth factors stimulate the mitogen- activated protein kinase signaling cascade in cardiac myocytes: the potential role of the cascade in the integration of two signaling pathways leading to myocyte hypertrophy. J Biol Chem. 1994;269:1110–1119.[Abstract/Free Full Text]

19. Padua RR, Merle PL, Doble BW, Yu CH, Zahradka P, Pierce GN, Panagia V, Kardami E. FGF-2-induced negative inotropism and cardioprotection are inhibited by chelerythrine: involvement of sarcolemmal calcium-independent protein kinase C. J Mol Cell Cardiol. 1998;30:2695–2709.[Medline] [Order article via Infotrieve]

20. Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J, Rapp U, Cooper GM. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol. 1997;17:732–741.[Abstract]

21. Jordan M, Schallhorn A, Wurm FM. Transfecting mammalian cells: optimization of critical parameters affecting calcium-phosphate precipitate formation. Nucleic Acids Res. 1996;24:596–601.[Abstract/Free Full Text]

22. Ping P, Zhang J, Cao X, Li RC, Kong D, Tang XL, Qiu Y, Manchikalapudi S, Auchampach JA, Black RG, Bolli R. PKC-dependent activation of p44/p42 MAPKs during myocardial ischemia- reperfusion in conscious rabbits. Am J Physiol. 1999;276:H1468–H1481.[Abstract/Free Full Text]

23. Kobayashi E, Nakano H, Morimoto M, Tamaoki T. Calphostin C (UCN-1028C), a novel microbial compound, is a highly potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1989;159:548–553.[Medline] [Order article via Infotrieve]

24. Kaufmann U, Martin B, Link D, Witt K, Zeitler R, Reinhard S, Starzinski-Powitz A. M-Cadherin and its sisters in development of striated muscle. Cell Tissue Res. 1999;296:191–198.[Medline] [Order article via Infotrieve]

25. Kardami E, Doble BW. Cardiomyocyte gap junctions: a target for growth factor signaling. Trends Cardiovasc Med. 1998;8:180–187.

26. Peters NS, Green CR, Poole-Wilson PA, Severs NJ. Cardiac arrhythmogenesis and the gap junction. J Mol Cell Cardiol. 1995;27:37–44.[Medline] [Order article via Infotrieve]

27. Yamasaki H, Naus CC. Role of connexin genes in growth control. Carcinogenesis. 1996;17:1199–1213.[Free Full Text]

28. Hossain MZ, Ao P, Boynton AL. Rapid disruption of gap junctional communication and phosphorylation of connexin43 by platelet-derived growth factor in T51B rat liver epithelial cells expressing platelet-derived growth factor receptor. J Cell Physiol. 1998;174:66–77.[Medline] [Order article via Infotrieve]

29. Kanemitsu MY, Lau AF. Epidermal growth factor stimulates the disruption of gap junctional communication and connexin43 phosphorylation independent of 12-O- tetradecanoylphorbol 13-acetate-sensitive protein kinase C: the possible involvement of mitogen-activated protein kinase. Mol Biol Cell. 1993;4:837–848.[Abstract]

30. Lampe PD. Analyzing phorbol ester effects on gap junctional communication: a dramatic inhibition of assembly. J Cell Biol. 1994;127:1895–1905.[Abstract/Free Full Text]

31. Matesic DF, Rupp HL, Bonney WJ, Ruch RJ, Trosko JE. Changes in gap-junction permeability, phosphorylation, and number mediated by phorbol ester and non-phorbol-ester tumor promoters in rat liver epithelial cells. Mol Carcinog. 1994;10:226–236.[Medline] [Order article via Infotrieve]

32. Kwak BR, Jongsma HJ. Regulation of cardiac gap junction channel permeability and conductance by several phosphorylating conditions. Mol Cell Biochem. 1996;157:93–99.[Medline] [Order article via Infotrieve]

33. Disatnik MH, Buraggi G, Mochly-Rosen D. Localization of protein kinase C isozymes in cardiac myocytes. Exp Cell Res. 1994;210:287–297.[Medline] [Order article via Infotrieve]

34. Disatnik MH, Jones SN, Mochly-Rosen D. Stimulus-dependent subcellular localization of activated protein kinase C: a study with acidic fibroblast growth factor and transforming growth factor-beta 1 in cardiac myocytes. J Mol Cell Cardiol. 1995;27:2473–2481.[Medline] [Order article via Infotrieve]

35. Doble BW, Merle P-L, Kardami E. Involvement of protein kinase C- in mediating growth factor induced phosphorylation of connexin43 at gap junctions of the intact cardiomyocyte. Circulation. 1998;98(suppl I):I-677. Abstract.

36. Calero G, Kanemitsu M, Taffet SM, Lau AF, Delmar M. A 17-mer peptide interferes with acidification-induced uncoupling of connexin43. Circ Res. 1998;82:929–935.[Abstract/Free Full Text]

37. Homma N, Alvarado JL, Coombs W, Stergiopoulos K, Taffet SM, Lau AF, Delmar M. A particle-receptor model for the insulin-induced closure of connexin43 channels. Circ Res. 1998;83:27–32.[Abstract/Free Full Text]

38. Stergiopoulos K, Alvarado JL, Mastroianni M, Ek-Vitorin JF, Taffet SM, Delmar M. Hetero-domain interactions as a mechanism for the regulation of connexin channels. Circ Res. 1999;84:1144–1155.[Abstract/Free Full Text]

39. Acs P, Bogi K, Lorenzo PS, Marquez AM, Biro T, Szallasi Z, Blumberg PM. The catalytic domain of protein kinase C chimeras modulates the affinity and targeting of phorbol ester-induced translocation. J Biol Chem. 1997;272:22148–22153.[Abstract/Free Full Text]

40. Cope DK, Impastato WK, Cohen MV, Downey JM. Volatile anesthetics protect the ischemic rabbit myocardium from infarction. Anesthesiology. 1997;86:699–709.[Medline] [Order article via Infotrieve]

41. Cacace AM, Guadagno SN, Krauss RS, Fabbro D, Weinstein IB. The epsilon isoform of protein kinase C is an oncogene when overexpressed in rat fibroblasts. Oncogene. 1993;8:2095–2104.[Medline] [Order article via Infotrieve]

42. Yamasaki H, Mesnil M, Omori Y, Mironov N, Krutovskikh V. Intercellular communication and carcinogenesis. Mutat Res. 1995;333:181–188.[Medline] [Order article via Infotrieve]

This article has been cited by other articles:

				W. Srisakuldee, M. M. Jeyaraman, B. E. Nickel, S. Tanguy, Z.-S. Jiang, and E. Kardami Phosphorylation of connexin-43 at serine 262 promotes a cardiac injury-resistant state Cardiovasc Res, September 1, 2009; 83(4): 672 - 681. [Abstract] [Full Text] [PDF]

				K. Boengler, R. Schulz, and G. Heusch Loss of cardioprotection with ageing Cardiovasc Res, July 15, 2009; 83(2): 247 - 261. [Abstract] [Full Text] [PDF]

				V. Akoyev, S. Das, S. Jena, L. Grauer, and D. J. Takemoto Hypoxia-Regulated Activity of PKC{epsilon} in the Lens Invest. Ophthalmol. Vis. Sci., March 1, 2009; 50(3): 1271 - 1282. [Abstract] [Full Text] [PDF]

				C.-L. Chen and H.-C. Chen Functional suppression of E-cadherin by protein kinase C{delta} J. Cell Sci., February 15, 2009; 122(4): 513 - 523. [Abstract] [Full Text] [PDF]

				E. N. Churchill, M.-H. Disatnik, G. R. Budas, and D. Mochly-Rosen Ethanol for cardiac ischemia: the role of protein kinase c Therapeutic Advances in Cardiovascular Disease, December 1, 2008; 2(6): 469 - 483. [Abstract] [PDF]

				S. F. Steinberg Structural Basis of Protein Kinase C Isoform Function Physiol Rev, October 1, 2008; 88(4): 1341 - 1378. [Abstract] [Full Text] [PDF]

				A. Salameh, S. Krautblatter, S. Baessler, S. Karl, D. R. Gomez, S. Dhein, and D. Pfeiffer Signal Transduction and Transcriptional Control of Cardiac Connexin43 Up-Regulation after {alpha}1-Adrenoceptor Stimulation J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 315 - 322. [Abstract] [Full Text] [PDF]

				S. Y. Lu, D. P. Sontag, K. A. Detillieux, and P. A. Cattini FGF-16 is released from neonatal cardiac myocytes and alters growth-related signaling: a possible role in postnatal development Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1242 - C1249. [Abstract] [Full Text] [PDF]

				M.-A. Meilleur, C. D. Akpovi, R.-M. Pelletier, and M. L. Vitale Tumor Necrosis Factor-{alpha}-Induced Anterior Pituitary Folliculostellate TtT/GF Cell Uncoupling Is Mediated by Connexin 43 Dephosphorylation Endocrinology, December 1, 2007; 148(12): 5913 - 5924. [Abstract] [Full Text] [PDF]

				T. Miura, T. Yano, K. Naitoh, M. Nishihara, T. Miki, M. Tanno, and K. Shimamoto {delta}-Opioid receptor activation before ischemia reduces gap junction permeability in ischemic myocardium by PKC-{varepsilon}-mediated phosphorylation of connexin 43 Am J Physiol Heart Circ Physiol, September 1, 2007; 293(3): H1425 - H1431. [Abstract] [Full Text] [PDF]

				V. Drobic, R. H. Cunnington, K. M. Bedosky, J. E. Raizman, V. V. Elimban, S. G. Rattan, and I. M. C. Dixon Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction Am J Physiol Heart Circ Physiol, August 1, 2007; 293(2): H1053 - H1064. [Abstract] [Full Text] [PDF]

				S. L. House, S. J. Melhorn, G. Newman, T. Doetschman, and J. E. J. Schultz The protein kinase C pathway mediates cardioprotection induced by cardiac-specific overexpression of fibroblast growth factor-2 Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H354 - H365. [Abstract] [Full Text] [PDF]

				K. Boengler, I. Konietzka, A. Buechert, Y. Heinen, D. Garcia-Dorado, G. Heusch, and R. Schulz Loss of ischemic preconditioning's cardioprotection in aged mouse hearts is associated with reduced gap junctional and mitochondrial levels of connexin 43 Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1764 - H1769. [Abstract] [Full Text] [PDF]

				K. Naitoh, Y. Ichikawa, T. Miura, Y. Nakamura, T. Miki, Y. Ikeda, H. Kobayashi, M. Nishihara, K. Ohori, and K. Shimamoto MitoKATP channel activation suppresses gap junction permeability in the ischemic myocardium by an ERK-dependent mechanism Cardiovasc Res, May 1, 2006; 70(2): 374 - 383. [Abstract] [Full Text] [PDF]

				S. Matsushita, H. Kurihara, M. Watanabe, T. Okada, T. Sakai, and A. Amano Alterations of Phosphorylation State of Connexin 43 during Hypoxia and Reoxygenation Are Associated with Cardiac Function J. Histochem. Cytochem., March 1, 2006; 54(3): 343 - 353. [Abstract] [Full Text] [PDF]

				D. Chung and R. L. Caruso 2,2'-Dichlorobiphenyl Decreases Amplitude and Synchronization of Uterine Contractions Through MAPK1-Mediated Phosphorylation of GJA1 (Connexin43) and Inhibition of Myometrial Gap Junctions Biol Reprod, November 1, 2005; 73(5): 974 - 982. [Abstract] [Full Text] [PDF]

				S. Dhein New, emerging roles for cardiac connexins. Mitochondrial Cx43 raises new questions Cardiovasc Res, August 1, 2005; 67(2): 179 - 181. [Full Text] [PDF]

				J. P. Stains and R. Civitelli Gap Junctions Regulate Extracellular Signal-regulated Kinase Signaling to Affect Gene Transcription Mol. Biol. Cell, January 1, 2005; 16(1): 64 - 72. [Abstract] [Full Text] [PDF]

				B. N.G Giepmans Gap junctions and connexin-interacting proteins Cardiovasc Res, May 1, 2004; 62(2): 233 - 245. [Abstract] [Full Text] [PDF]

				S. Dhein Pharmacology of gap junctions in the cardiovascular system Cardiovasc Res, May 1, 2004; 62(2): 287 - 298. [Abstract] [Full Text] [PDF]

				R. Schulz and G. Heusch Connexin 43 and ischemic preconditioning Cardiovasc Res, May 1, 2004; 62(2): 335 - 344. [Abstract] [Full Text] [PDF]

				D. Garcia-Dorado, A. Rodriguez-Sinovas, and M. Ruiz-Meana Gap junction-mediated spread of cell injury and death during myocardial ischemia-reperfusion Cardiovasc Res, February 15, 2004; 61(3): 386 - 401. [Abstract] [Full Text] [PDF]

				B. W. Doble, X. Dang, P. Ping, R. R. Fandrich, B. E. Nickel, Y. Jin, P. A. Cattini, and E. Kardami Phosphorylation of serine 262 in the gap junction protein connexin-43 regulates DNA synthesis in cell-cell contact forming cardiomyocytes J. Cell Sci., January 22, 2004; 117(3): 507 - 514. [Abstract] [Full Text] [PDF]

				T. Miura, Y. Ohnuma, A. Kuno, M. Tanno, Y. Ichikawa, Y. Nakamura, T. Yano, T. Miki, J. Sakamoto, and K. Shimamoto Protective role of gap junctions in preconditioning against myocardial infarction Am J Physiol Heart Circ Physiol, January 1, 2004; 286(1): H214 - H221. [Abstract] [Full Text] [PDF]

				J. C. SAEZ, V. M. BERTHOUD, M. C. BRANES, A. D. MARTINEZ, and E. C. BEYER Plasma Membrane Channels Formed by Connexins: Their Regulation and Functions Physiol Rev, October 1, 2003; 83(4): 1359 - 1400. [Abstract] [Full Text] [PDF]

				K. A. Detillieux, F. Sheikh, E. Kardami, and P. A. Cattini Biological activities of fibroblast growth factor-2 in the adult myocardium Cardiovasc Res, January 1, 2003; 57(1): 8 - 19. [Abstract] [Full Text] [PDF]

				U. Schwanke, I. Konietzka, A. Duschin, X. Li, R. Schulz, and G. Heusch No ischemic preconditioning in heterozygous connexin43-deficient mice Am J Physiol Heart Circ Physiol, October 1, 2002; 283 (4): H1740 - H1742. [Abstract] [Full Text] [PDF]

				D. Garcia-Dorado, M. Ruiz-Meana, F. Padilla, A. Rodriguez-Sinovas, and M. Mirabet Gap junction-mediated intercellular communication in ischemic preconditioning Cardiovasc Res, August 15, 2002; 55(3): 456 - 465. [Abstract] [Full Text] [PDF]

				C. P. Baines, J. Zhang, G.-W. Wang, Y.-T. Zheng, J. X. Xiu, E. M. Cardwell, R. Bolli, and P. Ping Mitochondrial PKC{epsilon} and MAPK Form Signaling Modules in the Murine Heart: Enhanced Mitochondrial PKC{epsilon}-MAPK Interactions and Differential MAPK Activation in PKC{epsilon}-Induced Cardioprotection Circ. Res., March 8, 2002; 90(4): 390 - 397. [Abstract] [Full Text] [PDF]

				J. L. Tuttle and J. C. Falcone Nitric oxide release during {alpha}1-adrenoceptor-mediated constriction of arterioles Am J Physiol Heart Circ Physiol, August 1, 2001; 281(2): H873 - H881. [Abstract] [Full Text] [PDF]

				M. Ruiz-Meana, D. Garcia-Dorado, S. Lane, P. Pina, J. Inserte, M. Mirabet, and J. Soler-Soler Persistence of gap junction communication during myocardial ischemia Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2563 - H2571. [Abstract] [Full Text] [PDF]

				R. M. Fryer, Y. Wang, A. K. Hsu, and G. J. Gross Essential activation of PKC-{delta} in opioid-initiated cardioprotection Am J Physiol Heart Circ Physiol, March 1, 2001; 280(3): H1346 - H1353. [Abstract] [Full Text] [PDF]

				J. B. Strait III, J. L. Martin, A. Bayer, R. Mestril, D. M. Eble, and A. M. Samarel Role of protein kinase C-{epsilon} in hypertrophy of cultured neonatal rat ventricular myocytes Am J Physiol Heart Circ Physiol, February 1, 2001; 280(2): H756 - H766. [Abstract] [Full Text] [PDF]

				Z.-S. Jiang, R. R. Padua, H. Ju, B. W. Doble, Y. Jin, J. Hao, P. A. Cattini, I. M. C. Dixon, and E. Kardami Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C Am J Physiol Heart Circ Physiol, March 1, 2002; 282(3): H1071 - H1080. [Abstract] [Full Text] [PDF]

				T. M. Vondriska, J. Zhang, C. Song, X.-L. Tang, X. Cao, C. P. Baines, J. M. Pass, S. Wang, R. Bolli, and P. Ping Protein Kinase C {epsilon}-Src Modules Direct Signal Transduction in Nitric Oxide-Induced Cardioprotection : Complex Formation as a Means for Cardioprotective Signaling Circ. Res., June 22, 2001; 88(12): 1306 - 1313. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Methods Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Doble, B. W. Articles by Kardami, E. Search for Related Content PubMed PubMed Citation Articles by Doble, B. W. Articles by Kardami, E. Related Collections Other myocardial biology Arrythmias-basic studies Cell signalling/signal transduction Growth factors/cytokines